STAAR/$STAA
1D1W1MYTD1Y5YMAX
Capital at risk
About STAAR
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
- Ticker
- $STAA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 921
- Headquarters
- Lake Forest, United States
- Website
- www.staar.com
STAAR Metrics
BasicAdvanced
$1.2B
299.93
$0.08
1.23
-
Price and volume
Market cap
$1.2B
Beta
1.23
52-week high
$35.87
52-week low
$15.59
Average daily volume
929K
Financial strength
Current ratio
4.665
Quick ratio
3.863
Long term debt to equity
0.081
Total debt to equity
0.098
Profitability
EBITDA (TTM)
49.764
Gross margin (TTM)
76.62%
Net profit margin (TTM)
1.13%
Operating margin (TTM)
12.15%
Effective tax rate (TTM)
77.91%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
5.65%
Return on equity (TTM)
1.09%
Valuation
Price to earnings (TTM)
299.926
Price to revenue (TTM)
3.391
Price to book
3.16
Price to tangible book (TTM)
3.48
Price to free cash flow (TTM)
-170.603
Free cash flow yield (TTM)
-0.59%
Free cash flow per share (TTM)
-0.135
Growth
Revenue change (TTM)
51.30%
Earnings per share change (TTM)
-103.98%
3-year revenue growth (CAGR)
3.54%
10-year revenue growth (CAGR)
15.58%
3-year earnings per share growth (CAGR)
-47.12%
10-year earnings per share growth (CAGR)
-13.38%
What the Analysts think about STAAR
Analyst ratings (Buy, Hold, Sell) for STAAR stock.
Analyst projections of the future price of STAAR stock.
Bulls say / Bears say
STAAR’s preliminary Q2 2026 net sales more than doubled year-over-year to $90 million, highlighting robust demand growth across its core markets. (Reuters(bitget.com))
The company returned to profitability in Q2 2026 with net income of $8.058 million, compared to a net loss of $16.8 million a year earlier, demonstrating a strong margin recovery. (Reuters(bitget.com))
Revenue gains were geographically diversified, driven by strong performance in China, broader Asia-Pacific, and double-digit sales growth in the Americas, underscoring a balanced global expansion. (Reuters(bitget.com))
China accounted for over 50% of Q2 2026 revenue, exposing STAAR to significant regional macroeconomic and regulatory risks, including distributor inventory normalization in China and potential government policy shifts. (MarketScreener(marketscreener.com))
EMEA net sales declined 1% year-over-year in Q2 2026, reflecting vulnerability to geopolitical instability and broader macroeconomic headwinds in the Middle East and surrounding regions. (Reuters(bitget.com))
Management cited ongoing ERP system implementation challenges as an operational risk that could disrupt supply chain efficiency and inventory management, potentially constraining future growth. (Reuters(bitget.com))
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
STAAR Financial Performance
Revenues and expenses
STAAR Earnings Performance
Company profitability
Upcoming events
No upcoming events
STAAR News
AllArticlesVideos
STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction
Business Wire5 days ago
STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer
Business Wire1 week ago
STAAR Surgical Q2 Earnings Call Highlights
MarketBeat1 month ago
Funds containing STAAR
AllEURUSDGBP
Fund name | Fund size | $STAA weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.07% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.06% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.06% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.03% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.